PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Psychosom Med. Author manuscript; available in PMC Jan 7, 2009.
Published in final edited form as:
PMCID: PMC2614887
NIHMSID: NIHMS70620
Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment
Gail Ironson, MD, PhD, Conall O’Cleirigh, PhD, Mary Ann Fletcher, PhD, Jean Philippe Laurenceau, PhD, Elizabeth Balbin, BS, Nancy Klimas, MD, Neil Schneiderman, PhD, and George Solomon, MD
From the Department of Psychology and Behavioral Medicine (G.I., C.O., J.P.L., E.B., N.S.), Department of Psychiatry (G.I., N.S.), Department of Medicine (M.A.F., N.K., N.S.), University of Miami, Coral Gables, Florida.
Address correspondence and reprint requests to Gail Ironson, MD, PhD, Department of Psychology and Behavioral Medicine, University of Miami, PO Box 248185, Coral Gables, FL 33124-2070. E-mail: gironson/at/aol.com
Objective
Most previous longitudinal studies demonstrating relationships between psychosocial variables and human immunodeficiency virus (HIV) disease progression utilized samples of gay men accrued before the era of highly active antiretroviral treatment (HAART), without including viral load (VL) as an indicator of disease progression or assessing the impact of medication adherence. This study sought to determine whether psychosocial variables would predict both CD4 and VL changes in a diverse sample assessed entirely during the era of HAART and accounting for adherence effects.
Methods
This longitudinal study assessed a multiethnic HIV+ sample (n = 177) of men and women in the midrange of illness (CD4 number between 150 and 500; no previous acquired immunodeficiency syndrome [AIDS]–defining symptom) every 6 months for 2 years. Hierarchical linear modeling was used to model change in CD4 and VL controlling for sociodemographics (age, gender, ethnicity, education) and medical variables (baseline CD4/VL, antiretroviral medications at each time point, adherence).
Results
Baseline depression, hopelessness, and education predicted the slope of CD4 and VL. Avoidant coping and life event stress predicted VL change. Cumulative variables produced stronger relationships (depression, avoidant coping, and hopelessness with CD4/VL slope and life events stress with VL slope). High cumulative depression and avoidant coping were associated with approximately twice the rate of decline in CD4 as low scorers and greater relative increases in VL. Social support was not significantly related to CD4 or VL slope.
Conclusions
Psychosocial factors contribute significantly to the variance in HIV disease progression (assessed through CD4 number and VL) in a diverse sample, accounting for adherence and do so in the era of HAART.
Keywords: HIV/AIDS, disease progression, adherence, depression, coping, stress
Studies, primarily conducted on gay men before the availability of highly active antiretroviral therapy (HAART), suggest that psychosocial variables may predict disease progression in human immunodeficiency virus (HIV). Thus, depression has been related to faster CD4 decline (1), progression to acquired immunodeficiency syndrome (AIDS) (25), and mortality (68). Similarly, stress has predicted faster CD4 cell decline (9,10), clinical symptoms (11,12), and progression to AIDS (3,4). Longitudinal studies of coping found that denial predicts greater CD4 decline (11), progression to AIDS (11,13,14), and mortality (11). Conversely, active coping predicted decreased clinical progression (15), AIDS (16), and lower mortality (17). Mixed results have been found in the literature for social support, with some studies showing higher social support predicting slower disease progression to AIDS (4), less rapid decline in CD4 cells (18), slower symptom onset (4,14), and longer survival (7). However, others found either no relationship between social support and disease progression (19) or higher social support predicting faster decline in CD4 (20). Only 1 study of psychosocial predictors was undertaken during the time of HAART, and it reported that depression predicted CD4 decline and mortality (8). However, this study only examined depression in women, and the accrual period (1993–1995) was completed before the availability of protease inhibitors (PIs).
The present longitudinal study expands on the above findings by reporting on a diverse sample of men and women conducted entirely during a period of widespread HAART/PI availability, by examining several psychosocial predictors in addition to depression, and by predicting the change in both CD4 cells and viral load (VL) over time. VL was not available when most of the earlier studies were undertaken. In addition, since some studies suggested that cumulative measurement of psychosocial variables could be important (6,8,13), a compareison of baseline and cumulative measurement of these variables was undertaken. The intent was to determine if the psychosocial variables would predict above both traditional control variables (i.e., age, race, gender, socioeconomic status [SES]), as well as medically important behaviors (i.e., adherence, initial disease status, medications prescribed). This was accomplished using a statistical methodology, hierarchical linear modeling (HLM), that allowed for the control of medication changes at every time point. CD4 cell counts and VL were chosen because of their ability to predict clinical outcomes (21,22).
Adherence to antiretroviral medications prescribed for the treatment of HIV is central to the effective management of the disease (2325). Poorer adherence to antiretroviral medications has been associated with more rapid HIV disease progression as measured by HIV-1 VL or CD4 cell counts (2630) and has been associated with the emergence of viral mutations which can result in medication resistance (23,28,31).
The relationship between medication adherence in HIV and psychosocial factors is well established. Poorer adherence has been related to stressful life events, depression, hopelessness and anxiety, lower social support, lower levels of patient knowledge about HIV, as well as characteristics of the treatment and treatment setting (3236). As medication adherence is of central importance to both HIV disease progression and sensitive to the psychosocial milieu of the patient, its relationship with the psychosocial predictors in this study and its relationship to the disease progression markers were also carefully considered.
Subjects
Participants were a paid volunteer sample recruited through physician offices, specialty clinics, service organizations, and hospitals. Subjects were included in this study if they were HIV positive and had CD4 cells between 150 and 500 at study entry, thus capturing people in the midrange of disease who we hypothesized would be most vulnerable to the possible impact of psychosocial factors on HIV disease. Subjects were excluded if they had ever experienced an AIDS-defining (Category C) symptom, ever had CD4 cells below 75, were under age 18, had other life-threatening illnesses (e.g., cancer), were actively psychotic or suicidal, had dementia or current alcohol or drug dependence or current IV use.
Design
This study used a longitudinal design where participants were assessed every 6 months for a period of 2 years. The accrual period lasted 2.5 years, and the study period was from 1997 to 2002.
Procedures
At baseline, subjects completed written informed consent, psychosocial questionnaires, a clinical assessment interview, and blood draw for CD4 and VL assay. Follow-up visits, repeated every 6 months, included the questionnaire battery, brief interview, and blood draw. Study procedures, including informed consent, were approved by the institutional review board.
Measures
Demographics and background medical information (see Table 1) were assessed by self-report. Prescribed medications and adherence were assessed through interviewer-administered AIDS Clinical Trials Group (ACTG) Adherence Measure (32). Adherence was calculated as the percentage of missed doses averaged over each assessment time point for which the subject was taking medications. Past drug/alcohol abuse and dependence and psychotic symptoms were assessed using the interviewer administered Structured Clinical Interview Diagnostic-Diagnostic and Statistical Manual-III-R.
TABLE 1
TABLE 1
Background and Medical Information
Disease Progression Markers
CD4 lymphocyte count (CD3+CD4+) was determined by whole-blood 4-color direct immunofluorescence using a coulter XL-MCL flow cytometer. VL utilized the Roche Amplicor RT/PCR assay sensitive to 400 copies of plasma RNA.
Psychosocial Measures
Depression was assessed by the Beck Depression Inventory (BDI) (37), a 21-item scale of cognitive, affective, and behavioral symptoms of depression over the past week, which includes subscales for affective and somatic symptoms (38). Hopelessness was measured by the Beck Hopelessness Scale (BHS) (39), a 20-item true/false questionnaire that examines feelings about the future, loss of motivation, and expectations. Coping strategies were assessed using the COPE (40), a 24-item scale, modified for HIV populations, which assesses the endorsement of each of 12 cognitive and behavioral coping strategies. Two subscales, denial and behavioral disengagement, were combined for an avoidant coping composite because of previous work relating them to disease outcomes in HIV (4,11,14). Life event stress was assessed using the Sarason et al. (41) life events scale sum of the weighted (−3 to +3) negative life events excluding health related events. Social support was assessed using the ENRICHED Social Support Instrument (ESSI) (42), a 7-item scale assessing support over the past month, with 1 item asking if participants were married/partnered or not. Cumulative average psychosocial measures were calculated by averaging the patients’ score from each of the first 4 assessment time points that were completed. This measure would be higher, for example, in patients who are chronically depressed rather than depressed at only baseline and provides a more reliable measure than single baseline assessment.
Statistical Methods
The main analyses used HLM (43,44) to model CD4 and VL change. HLM was chosen because it permits control for antiretroviral use at each time point, allows for prediction of slope, and the calculation of expected changes in CD4 and VL for each predictor. Variance in disease progression markers is separated into 2 levels: Level 1 represents a growth model for each individual capturing within-person change in CD4 and VL over repeated measurements. Level 2 represents a model of interindividual differences in parameters of individual change and uses between-person characteristics (e.g., depression) to predict change. Thus, systematic variability of the slopes and intercepts at level 1 are modeled by predictors at level 2.
Covariate Selection
Level 1 covariates included prescribed antiretroviral medication (as a time-dependent covariate), time since baseline (months), and the interactions of these terms. Time since baseline reflected the length of time each of the 5 repeated assessments were conducted relative to baseline and generated the structure of the latent slope and intercept. Antiretroviral medications were dummy coded at each time point, reflecting 3 levels: no medication, combination therapy, or HAART. The demographic variables of race (coded 1 = non-Hispanic Caucasian, 0 = other), gender (coded 1 = male, 0 = female), age, education level (coded 0 = less than high school, 1 = some high school, 2 = high school graduate, 3 = trade-school or some college, 4 = college graduate, 5 = graduate degree) were included as a priori covariates relevant to HIV (45,46). Education level was used as a relatively unbiased indicator of SES because income and employment may be affected by advancing HIV disease. Initial disease status was also controlled in the level 2 model using baseline CD4 number or VL log10 to account for the possibility that initial level of CD4 or VL may be related to change over time. The covariates were included, a priori, in the level 2 model at the slope (the outcome of interest) and remained in both CD4 and VL models for all subsequent analysis. All continuous variables in the model were centered, and all categorical variables were coded with zero as the lowest level. Because VL was skewed, it was transformed using a log10 transformation.
Medication Adherence
As only 77% of the sample were taking antiretroviral medication at study entry and only 90% of the sample were taking medications at any time during the study, medication adherence data were only available on a subset of the whole sample (n = 160). Because of the central role of adherence in optimal management of HIV, the main analyses were rerun to determine whether the significance of the psychosocial variables on disease progression was independent of adherence.
Description of the Sample
Demographic and medical information is presented in Table 1. Our sample (n = 177) was diverse in terms of gender, ethnicity, and sexual orientation. Most participants were of low to moderate SES, many were on disability or unemployed, and about one-third of the sample had a history of alcohol/drug abuse. At study entry, the average CD4 count was 297 and mean HIV VL was 44,861. Over 2 years of follow-up, 90% of patients had taken antiretroviral medications. Table 2 gives descriptive information for the psychosocial predictors.
TABLE 2
TABLE 2
Means and Standard Deviations of Baseline and Cumulative Psychological Predictors of HIV Disease Progression Markers
Prediction to CD4 Change Over Time
Basic Model
Table 3 contains the basic equations (and explanation of terms) for the HLM model, and Table 4 includes the results and significance tests for the basic model for predicting CD4 change/slope controlling for antiretroviral medications and other covariates. There is a significant linear decrease in CD4 over time (γ10) controlling for covariates. The model indicates that average CD4 level at study entry is 285.52, and this decreased at a rate of 4.45 CD4 cells/month (about 53 cells/yr) above and beyond the effects of medications for minority women of low SES (i.e., categorical variables coded 0). There is also significant individual variation in CD4 change over time (χ2 (170) = 415.48, p = < .001).
TABLE 3
TABLE 3
The Basic Equations for Predicting Changes (Slope) in CD4 or VL(Log)a With Explanation of Terms
TABLE 4
TABLE 4
Basic Model Including Coefficients and Significance Tests for Level 1 and Level 2 Covariates in Prediction of CD4 Slope Over 2 Years
Covariates
At level 1 (see Table 4), there is a significant increase in CD4 attributable to changes in being on combination therapy or HAART (γ40 and γ50). At level 2, higher education and higher baseline CD4 buffered CD4 decline.
The Contribution of Psychological Variables
Baseline Predictors
Faster CD4 decline was predicted from baseline depression (γ16), hopelessness (γ16), and social support (γ16; trend) but not from avoidant coping or life event stress (Table 5a). Subsequent analysis restricting the BDI to the cognitive/affective subscale only showed a continued tendency toward significance (γ16 = −0.130, t(170) = −1.602, p = .11).
TABLE 5
TABLE 5
Prediction From Baseline Psychosocial Variables and Association With Cumulative Psychosocial Variables to CD4 Slope (A) With Additional Control for Antiretroviral Medication Adherence (B)
Relationship to Cumulative Variables
Cumulative depression, hopelessness, and avoidant coping were more strongly related to CD4 decline than baseline measures. The cognitive/affective subscale of the BDI was also significantly related to CD4 decline (γ16 = −0.189, t(170) = −1.936, p = .05), as were both denial (γ16 = −1.160, t(170) = −2.652, p = .009) and behavioral disengagement (γ16 = −1.12, t(170) = −2.127, p = .035). Cumulative life events stress and social support were not significantly related to CD4 change.
Clinical Translation
Decline ratios (DRs) were calculated to compare the impact of the high and low levels (75th and 25th percentile) of each psychological variable on CD4 and VL change (see Table 5a). The formula for the calculation of the DR is: DR = [γ10 + γ16 (75th percentile score − mean)]/[γ10 + γ16 (25th percentile score − mean)], where γ10 is the average rate of CD4 decline controlling for other covariates in the model and γ16 is the increment in CD4 decline for every point above or below the mean of the psychological variable. Cumulative depression provides an illustrative example. The rate of decline for those of average depression (γ10) is −3.36 CD4 cells per month (run with BDI in the model), and the increment for each point from the mean of depression (γ16) is −0.21. The 75th and 25th percentile scores in cumulative depression were 14.25 and 4.25, respectively, which were 4.20 and −5.80 points from the mean, respectively. The rate of CD4 cell decline for those at the 25th percentile in depression is given by (−3.36) + [(−0.21) (−5.80)] = 2.14 per month, or approximately 26 per year. The rate of CD4 cell decline for those at the 75th percentile in depression is given by (−3.36) + [(−0.21) (4.20)] = 4.24 cells per month, or approximately 51 per year. Thus those scoring at the 75th percentile in cumulative depression lose their CD4 cells at almost twice the rate compared with those at the 25th percentile, as indicated by DR = 1.96.1 Increase ratios for VL log are calculated in a parellel fashion (Table 7a).
TABLE 7
TABLE 7
Prediction From Baseline Psychosocial Variables and Association With Cumulative Psychosocial Variables of Log Viral Load Slope (A) With Additional Control for Antiretroviral Medication Adherence (B)
Other DRs for the significant psychosocial predictors are presented in Table 5a.
Prediction to VL Change Over Time
Basic Model (Table 6)
VL significantly increased over time (γ10), controlling for covariates. Patients had an average of 4.38 VL log units at study entry and increased 0.014 U/month (0.168 log units/yr). Individual variation around the slope of VL (change) was also significant (χ2 (170) = 235.62, p = .001)
TABLE 6
TABLE 6
Basic Model Including Coefficients and Significance Tests for Level 1 and Level 2 Covariates in Prediction of Viral Load (Log) Slope Over 2 Years
Covariates (Table 6)
Antiretroviral medications were significantly associated with lower levels of VL (γ20, γ30). Only education was significantly related to log VL slope (t(171) = −2.207, p = .029).
The Contribution of Psychological Variables
Prediction From Baseline Variables (Table 7a)
Higher baseline depression (BDI), hopelessness (BHS), negative life events, and avoidant coping (COPE) predicted greater VL increase. The cognitive/affective subscale of the BDI showed similar results (γ16 = 0.1073 × 10−2, t(170) = 2.325, p = .021), as did both denial (γ16 = 0.433 × 10−2, t(170) = 2.655, p = .009) and behavioral disengagement (γ16 = 0.608 × 10−2, t(170) = 3.298; p = .002). Baseline levels of social support were not significantly related to VL change over time.
Relationship to Cumulative Variables (Table 7a)
Cumulative depression, hopelessness, negative life events, and avoidant coping maintained their significant association with VL change. The COPE subscales of denial (γ16 = 0.614 × 10−2, t(170) = 2.293, p = .023) and behavioral disengagement (γ16 = 0.896 × 10−2, t(170) = 3.734, p = .001) were also significantly related to VL increase, as was the cognitive/affective subscale of the BDI (γ16 = 0.150 × 10−2, t(170) = 2.697, p = .008). Cumulative measures of social support were not significantly related to VL change.
Clinical Translation (Table 7a)
Those with high baseline depression scores (75th percentile) experienced close to a threefold increase in VL as compared with those with low scores (25th percentile). The largest baseline increase ratio (6.41) was observed for avoidant coping. The largest cumulative increase ratio was found for depression (7.44).
Medication Adherence
Cumulative self-reported medication adherence was significantly related to each of the psychosocial predictors, except social support (see Table 8). Medication adherence was significantly associated with slope of VL (γ16=0.042, t(153)=2.539, p = .012) but not to CD4 change (γ16 = −3.22, t(153) = −0.979, p = .330). Controlling for medication adherence in these models did not alter the significance of any of the relationships found in the main analyses (see Table 5b and Table 7b), with the exception of life events stress, which had significantly predicted VL change but now showed only a trend (p = .055).
TABLE 8
TABLE 8
The Interrelationship (Pearson Correlations) Between Self-Reported Antiretroviral Medication Adherence and Psychosocial Predictors (Depression, Hopelessness, Avoidant Coping, Life Event Stress, and Social Support)
These results provide evidence that even in the era of powerful HAART medications, psychosocial variables still account for significant variation in CD4 cell number and do so for VL as well. The results provide valuable confirmation of earlier studies (6,11,13) that established these relationships for depression, negative life events, and coping before the availability of HAART. In addition to depression, our results establish that hopelessness and denial/avoidant coping have significant relationships with both CD4 and VL changes over time and extend findings to both men and women with access to HAART throughout the entire period of the study. This is the first study of which we are aware that establishes a prospective relationship between hopelessness, denial/avoidant coping, life event stress, and accelerated rate of increase in VL. (A prospective relationship between depression and VL has previously been noted for women (8).) In fact, plasma VLs may be more sensitive to psychological influences than CD4, as indicated by higher increase and decline ratios.
Although many studies have found that depression and other psychological variables predict disease progression in HIV, none, to our knowledge, have controlled for adherence. This has become particularly important in the era of HAART as it has been estimated that adherence rates of up to 95% are required for achieving and maintaining viral suppression (26,27). It is interesting to note that in our study, medication adherence was significantly related to VL change, but not to CD4 change. Although the reason for this is not known, it raises the possibility that VL may be more immediately responsive to antiretroviral medications than CD4 cell reconstitution, which may require a longer period of time.
Our results provide information on the predictive relationships from both baseline and repeated measures of stress, distress, and coping. The presence of a significant relationship between cumulative avoidant coping with rate of CD4 change over time compared with the absence of a significant relationship with baseline supports the use of repeated assessments over time. The superior predictive power of repeated measures over baseline measures has been noted by others (5,6,8,13) and may help to explain some of the contrary findings relating depression to disease progression when depression was only measured at baseline (47).
Surprisingly, not only did no significant results emerge between social support and disease progression but a nonsignificant trend was observed whereby higher levels of baseline social support predicted more rapid CD4 decline. This puzzling result has some support in the existent literature (20) but is not consistent with results of several other studies which identified beneficial relationships (4,7). Subsequent analyses of our data revealed that higher levels of social support were associated with being sexually active (r = 0.27, p < .001) (assessed through interview) but were not associated with unsafe sex practices (r = 0.00, not significant). Notable aspects of this study that may be related to the absence of social support findings include the restriction of study participants to those in the midrange of disease, the exclusion of IV and dependent drug users, and the use of a measure that has items but not subscales for emotional, instrumental, and informational support.
Education was the only sociodemographic covariate significantly related both to rate of CD4 and VL change. The SES-health gradient is well established in the general literature (48), but this study is the first of which we are aware to predict changes in both biological markers of disease progression in HIV.
There are a number of plausible behavioral and biological mechanisms that have been suggested in explaining the link between depression/stress and disease progression (5,49). In this sample, adherence to medication does not explain the effect. Alterations in the hypothalamic-pituitary-adrenocortical system, including cortisol, have been demonstrated both in stress and depression, have been predictive of faster disease progression in HIV (4,13), and may stimulate HIV replication (50). Similarly, products of the sympathetic nervous system (norepinephrine) become elevated during stress and have been shown to enhance HIV viral replication in vitro (51,52). Important immune variables, including cytotoxic T lymphocytes and natural killer cells, undergo change during depression in HIV patients and have been related to symptom onset and disease progression in HIV (53,54).
Limitations
Although psychosocial variables were related to important markers of disease progression (i.e., CD4, HIV VL) that are known to predict clinical outcomes (21,22), the relatively short follow-up time of this study precluded predicting to clinical symptoms or death. The longitudinal design allows for the statement of predictive but not necessarily causal relationships between our baseline psychosocial variables and disease progression markers. Another limitation of the study was that the psychosocial (e.g., negative life events) and control (e.g., medication adherence) measures are based on self-reports and are vulnerable to the biases of that methodology. For example, it has been reported that life events stress measured by interview predicts CD4 change (3), whereas the present study using self-report assessment did not (although it did predict to VL). Finally, although changes in depression were carefully measured across assessments, the treatment of depression was not tracked and was not part of these analyses.
Conclusions and Future Directions
In summary, the present study demonstrated that several psychosocial factors contribute to the variance in HIV disease progression even in the present era of HAART medication. In particular, feelings of hopelessness, depressed mood, and avoidant coping predict an accelerated decline in CD4 cells and an increase in HIV VL. Pharmacologic (55,56) and behavioral treatments (57,58) have been shown to decrease depression in HIV patients. To the extent that these treatments may also attenuate both depressed affect and disease progression, large scale clinical intervention trials are needed to determine whether reducing distress and hopelessness, and improving adaptive coping skills in HIV infected individuals can decrease disease progression. Recent findings from a study of stress management in gay men with HIV (59) suggests that this may be the case, at least for VL.
Thanks to Kelly Detz for data management and to Annie George for conducting many of the interviews.
Acknowledgments
This research was graciously supported by the National Institute of Mental Health Grant (R01MH53791 and R01MH066697) Principal Investigator: Gail Ironson, T32MH18917 and Action for AIDS Foundation.
Glossary
HAARThighly active antiretroviral treatment
VLviral load
HIVhuman immunodeficiency virus
AIDSacquired immunodeficiency syndrome
PIprotease inhibitor
HLMhierarchical linear modeling
DRdecline ratio
SESsocioeconomic status
BDIBeck Depression Inventory
BHSBeck Hopelessness Scale
N/Anot applicable

Footnotes
1An alternative method for assessing the impact of repeated measures of depressive symptomology on HIV disease progression markers utilized by Ickovics and colleagues (8) identified those with limited, intermittent, and chronic depression based upon the number of assessment points at which the participant had depression scores above a clinical cutoff score corresponding to the 80th percentile. Applying the same methodology within this sample yielded a trichotomous variable that was significantly associated with both CD4 (γ16 = −1.73, t(170) = −2.241, p = .026) and VL change (γ16 = −1.38 × 10−2, t(170) = 3.391, p = .001) whereby those with chronic depression experienced a loss of CD4 cells at 2.02 times the rate and an increase in VL at 5.00 times the rate as those with limited or no depression. These results are consistent with the results of the main analyses.
1. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573. [PubMed]
2. Page-Shafer K, Delorenze GN, Satariano WA, Winkelstein W., Jr Co-morbidity and survival in HIV-infected men in the San Francisco Men’s Health Survey. Ann Epidemiol. 1996;6:420–430. [PubMed]
3. Leserman J, Jackson ED, Petitto JM, Golden RN, Silva SG, Perkins DO, Cai J, Folds JD, Evans DL. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397–406. [PubMed]
4. Leserman J, Petitto JM, Gu H, Gaynes BN, Barroso J, Golden RN, Perkins DO, Folds JD, Evans DL. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32:1059–1073. [PubMed]
5. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry. 2003;54:295–306. [PubMed]
6. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med. 1996;156:2233–2238. [PubMed]
7. Patterson TL, Shaw WS, Semple SJ, Cherner M, McCutchan A, Atkinson H, Grant I, Nannis E. Relationship of psychosocial factors to HIV disease progression. Ann Behav Med. 1996;18:30–39. [PubMed]
8. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1460–1465. [PubMed]
9. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, McCutchan JA, Straits-Troster K, Chandler JL, Grant I. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men: HIV Neurobehavioral Research Center Group. Psychiatry. 1995;58:299–312. [PubMed]
10. Kemeny ME, Dean L. Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDS Educ Prev. 1995;7(suppl):36–47. [PubMed]
11. Ironson G, Friedman A, Klimas N, Antoni M, Fletcher M, LaPerriere A, Simoneau J, Schneiderman N. Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus. Int J Behav Med. 1994;1:90–105. [PubMed]
12. Coates TJ, Stall R, Ekstrand M, Solomon G. Psychological predictors as cofactors for disease progression in men infected with HIV: the San Francisco men’s health study; Presented at the V International AIDS Conference; Montreal, Canada. 1989.
13. Leserman J, Petitto JM, Golden RN, Gaynes BN, Gu H, Perkins DO, Silva SG, Folds JD, Evans DL. Impact of stressful life events, depression, social support, coping and cortisol on progression to AIDS. Am J Psychiatry. 2000;157:1221–1228. [PubMed]
14. Solano L, Costa M, Salvati S, Coda R, Aiuti F, Mezzaroma I, Bertini M. Psychosocial factors and clinical evolution in HIV-1 infection: a longitudinal study. J Psychosom Res. 1993;37:39–51. [PubMed]
15. Mulder CL, Antoni MH, Dulvenvoorden HJ, Kauffmann RH, Goodkin K. Active confrontational coping predicts decreased clinical progression over a one-year period in HIV-infected homosexual men. J Psychosom Res. 1995;39:957–965. [PubMed]
16. Vassend O, Eskild A, Halvorsen R. Negative affectivity, coping, immune status, and disease progression in HIV infected individuals. Psychol Health. 1997;12:375–388.
17. Blomkvist V, Theorell T, Jonsson H, Schulman S, Berntorp E, Stiegendal L. Psychosocial self prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection. Psychother Psychosom. 1994;62:185–192. [PubMed]
18. Theorell T, Blomvist V, Jonsson H, Schulman S, Berntorp E, Stigendal L. Social support and the development of immune function in human immunodeficiency virus infection. Psychosom Med. 1995;57:32–35. [PubMed]
19. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry. 1992;49:396–401. [PubMed]
20. Miller G, Kemeny M, Taylor S, Cole S, Visscher B. Social relationships and immune processes in HIV seropositive gay and bisexual men. Ann Behav Med. 1997;19:139–151. [PubMed]
21. Sage MS, Holodnly M, Kuirzkes DR, O’Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med. 1996;2:625–629. [PubMed]
22. Powderly WG, Landry A, Lederman M. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA. 1998;280:72–77. [PubMed]
23. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations from the International AIDS Society–USA Panel. JAMA. 2000;283:381–390. [PubMed]
24. Kalichman SC, Ramachandran B, Ostrow D. Protease inhibitors and the new AIDS combination therapies: implications for psychological services. Prof Psychol Res Pract. 1998;29:349–356.
25. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385–391. [PubMed]
26. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, Holmes KK. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15:803–810. [PubMed]
27. Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner JS, Hogg RS. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care. 2004;16:446–457. [PubMed]
28. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy MG, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366. [PubMed]
29. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124–133. [PubMed]
30. Stansell J, Holtzer C, Mayer S, DeGuzman D, Hamel E, Lapins D. Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 2001. Factors affecting treatment outcomes in a medication event monitoring system.
31. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–1983. [PubMed]
32. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Patient Care Committee and Adherence Working Group of the Adult AIDS Clinical Trials Group: self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the ACTG adherence instruments. AIDS Care. 2000;12:255–266. [PubMed]
33. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient-and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 1997;54:91–98. [PubMed]
34. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998;10:297–312. [PubMed]
35. O’Cleirigh C, Ironson G. Poster presented to the 23rd Annual Conference of the Society for Behavioral Medicine. Boston, MA: 2005. The relationship between emotional processing of traumatic life experiences, distress and antiretroviral medication adherence in gay and bisexual HIV positive men.
36. Riera M, La Fuente LdL, Castanyer B. Adherence to antiretroviral therapy measured by pill count and drug serum concentrations: variables associated with a bad adherence. Med Clin. 2002;119:286–262. [PubMed]
37. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psych. 1961;4:561–571. [PubMed]
38. Kendall PC, Hollon SD, Beck AT, Hammen CL, Ingram RE. Issues and recommendations regarding use of the Beck Depression Inventory. Cogn Ther Res. 1987;11:289–299.
39. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the Hopelessness Scale. J Consult Clin Psychol. 1974;42:861–865. [PubMed]
40. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56:267–283. [PubMed]
41. Sarason IG, Johnson J, Siegel J. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychology. 1978;46:932–946. [PubMed]
42. Mitchell PH, Powell L, Blumenthal J, Norten J, Ironson G, Pitula CR, Froelicher ES, Czajkowski S, Youngblood M, Huber M, Berkman LF. A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. J Cardiopulm Rehabil. 2003;23:398–403. [PubMed]
43. Raudenbush SW, Bryk AS, Cheong YF, Congdon RC. HLM5: Hierarchical Linear and Nonlinear Modeling. Lincolnwood, IL: Scientific Software International; 2002.
44. Bryk AS, Raudenbush SW. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage; 2002.
45. Balbin EG, Ironson GH, Solomon GF. Stress and coping: the psycho-neuroimmunology of HIV/AIDS. Best Pract Res Clin Endocrinol Metab. 1999;13:615–633. [PubMed]
46. Kiecolt-Glaser JK, Glaser R. Methodological issues in behavioral immunology research with humans. Brain Behav Immunol. 1988;2:67–78. [PubMed]
47. Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, VanRaden MJ, Treisman GJ, Morgenstern H. Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA. 1993;270:2563–2567. [PubMed]
48. Adler NE, Boyce T, Chesney MA, Cohen S, Folkman S, Kahn RL, Syme SL. Socioeconomic status and health; the challenge of the gradient. Am Psychol. 1994;49:15–24. [PubMed]
49. Kopnisky KL, Stoff DM, Rausch DM. Workshop report: the effects of psychological variables on the progression of HIV-1 disease. Brain Behav Immunol. 2004;8:246–261. [PubMed]
50. Corley PA. Acquired immune deficiency syndrome: the glucocorticoid solution. Med Hypotheses. 1996;47:49–54. [PubMed]
51. Cole SW, Korin YD, Fahey JL, Zack JA. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol. 1998;161:610–616. [PubMed]
52. Cole SW, Naliboff BD, Kemeny ME, Griswold MP, Fahey JL, Zack JA. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A. 2001;98:12695–12700. [PubMed]
53. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry. 1997;154:630–634. [PubMed]
54. Ironson G, Balbin E, Solomon G, Schneiderman N, Fahey J, Fletcher MA. Relative preservation of natural killer cell cytotoxicity and number in healthy AIDS patients with low CD4 counts. AIDS. 2001;15:2065–2072. [PubMed]
55. Zisook S, Perterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. J Clin Psychiatry. 1998;59:217–224. [PubMed]
56. Rabkin J, Wagner G, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101–107. [PubMed]
57. Markowitz J, Kocsis J, Fishman B, Spielman L, Jocobsberg L, Frances A, Klerman G, Perry S. Treatment of depressive symptoms in HIV-positive patients. Arch Gen Psychiatry. 1998;55:452–457. [PubMed]
58. Safren S, Hendriksen E, Mayer K, Mimiaga M, Pickard R, Otto M. Cognitive behavioral therapy for HIV medication adherence and depression. Cogn Behav Pract. 2004;11:415–423.
59. Antoni M, Carrioo AW, Duran RE, Spitzer S, Penedo F, Ironson G, Fletcher MA, Klimas N, Schneiderman N. Randomized clinical trial of cognitive behavioral stress management on HIV viral load in gay men treated with HAART. Psychosom Med. in press. [PubMed]